1
|
Fernández-Ferreiro A, González Barcia M, Gil-Martínez M, Vieites-Prado A, Lema I, Argibay B, Blanco Méndez J, Lamas MJ, Otero-Espinar FJ. In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan. Eur J Pharm Biopharm 2015; 94:342-51. [PMID: 26079831 DOI: 10.1016/j.ejpb.2015.06.003] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 05/20/2015] [Accepted: 06/08/2015] [Indexed: 11/17/2022]
Abstract
Gellan gum, kappa-carrageenan and alginates are natural polysaccharides able to interact with different cations that can be used to elaborate ion-activated in situ gelling systems for different uses. The interaction between fluid solutions of these polysaccharides and cations presents into the tear made these biopolymers very interesting to elaborate ophthalmic drug delivery systems. The main purpose of this study is to evaluate the ability of mixtures of these polymers to obtain ion-activated ophthalmic in situ gelling systems with optimal properties for ocular use. To achieve this purpose different proportion of the biopolymers were analyzed using a mixture experimental design evaluating their transparency, mechanical properties and bioadhesion in the absence and presence of simulated tear fluid. Tear induces a rapid sol-to-gel phase transition in the mixtures forming a consistent hydrogel. The solution composed by 80% of gellan gum and 20% kappa-carrageenan showed the best mechanical and mucoadhesive properties. This mixture was evaluated for rheological behavior, microstructure, cytotoxicity, acute corneal irritancy, ex-vivo and in vivo ocular toxicity and in vivo corneal contact time using Magnetic Resonance Images (MRI) techniques. Result indicates that the system is safe at ophthalmic level and produces an extensive ocular permanence higher than 6h.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain; Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Miguel González Barcia
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - María Gil-Martínez
- Instituto Oftalmológico Gómez-Ulla, Rúa de Maruxa Mallo, 3, Santiago de Compostela 15706, Spain
| | - Alba Vieites-Prado
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Isabel Lema
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain; Surgery Department (Ophthalmology), Faculty of Optics and Optometry, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain
| | - Barbara Argibay
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - José Blanco Méndez
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain
| | - Maria Jesus Lamas
- Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS), Travesía Choupana s/n, Santiago de Compostela 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
| | - Francisco Javier Otero-Espinar
- Pharmacy and Pharmaceutical Technology Department and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15782, Spain.
| |
Collapse
|